Our broad expertise, end-to-end services and ability to begin immediate collaboration with government, commercial and academic partners in more than 60 countries make us uniquely positioned to support the COVID-19 response. We address emerging pandemics, epidemics and outbreaks with expertise that supports health and research efforts globally. We are experienced in addressing the complex aspects of infectious diseases — from infection prevention and control to clinical research on diagnostics, vaccines and treatment.
FHI Clinical goes where our expertise is needed. Whether it requires working from a state-of-the-art facility or in a low-tech, rural setting, we provide services tailored to meet your study needs, from protocol design and site assessments to trial planning, implementation and management.
FHI Clinical has long-standing relationships, a local team and broad expertise in sub-Saharan Africa. We're ready to help you confidently expand your research across the region, finding the best-fit countries and populations for your target indication and study type.
For more than 10 years, the FHI Clinical project team has partnered with companies developing and deploying vaccines, treatments and preventive devices for malaria in 35 countries worldwide.
For nearly 20 years, the FHI Clinical project team has partnered with companies developing and deploying vaccines, treatments and diagnostic tests for multiple oncology indications.
With infectious disease outbreaks, expanding immunity from previous infection and vaccination efforts can change where the outbreak is occurring. In this video, Loice Magaria, Clinical Research Project Manager at FHI Clinical discusses strategies implemented to address changing epidemiology in a study investigating COVID-19 treatments.
In this plenary discussion, experts in infectious diseases discuss how real-world epidemiology data, site capacity data and biosurveillance methodology could help identify TB-prevalent populations during protocol design, helping to ensure an adequate sample for TB vaccine development.
The study team maintained a 91% retention rate in a study of a Chikungunya virus (CHIKV) vaccine, despite study disruptions due to natural disasters, including Hurricane Maria, and political unrest near the sites in five Caribbean countries in a CHIKV endemic region.
Targeted geographic areas for the development of an antimalarial drug by Novartis included malaria-endemic regions in Africa and Asia, and Novartis requested assistance identifying and assessing potential clinical sites for their planned clinical trial. Our team conducted 38 rapid, in-depth, 2.5-day site feasibility assessments in the 18 countries.
CHIKV outbreaks have occurred in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. It was found for the first time in the Americas on islands in the Caribbean in 2013 and has spread throughout most of the Americas. It has since been identified in over 60 countries in Asia, Africa, Europe and the Americas. No commercially available vaccine to prevent or medicine to treat CHIKV infection is currently available.